Spiral Therapeutics completes a Serie A financing of $3.7 million

by Gemma Escarré,

Spiral Therapeutics, CataloniaBio & HealthTech member, secured $3.7 million as part of a Series A financing round co-led by Savoir Capital and Camden Partners to continue to advance its pipeline.

Specifically, the clinical stage pharmaceutical company will initiate the Phase I clinical trial of LPT99, its lead investigational drug candidate targeting prevention and treatment of hearing loss.

Spiral was launched in early 2016 by Hugo Peris and is headquartered in the San Francisco Bay Area. Its R&D lab is located in Barcelona. Peris is a board member of Salvat.

More information

Photo: Hugo Peris, founder and CEO of Spiral - © Spiral Therapeutics


To comment, please login or create an account